Market closed
Puma Biotechnology/PBYI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Puma Biotechnology
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Ticker
PBYI
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
185
Website
PBYI Metrics
BasicAdvanced
$137M
Market cap
15.38
P/E ratio
$0.18
EPS
1.07
Beta
-
Dividend rate
Price and volume
Market cap
$137M
Beta
1.07
52-week high
$7.73
52-week low
$2.13
Average daily volume
246K
Financial strength
Current ratio
1.32
Quick ratio
1.198
Long term debt to equity
99.155
Total debt to equity
203.234
Interest coverage (TTM)
1.45%
Management effectiveness
Return on assets (TTM)
6.01%
Return on equity (TTM)
22.17%
Valuation
Price to earnings (TTM)
15.383
Price to revenue (TTM)
0.612
Price to book
2.8
Price to tangible book (TTM)
-18.11
Price to free cash flow (TTM)
4.034
Growth
Revenue change (TTM)
-4.75%
Earnings per share change (TTM)
-397.00%
3-year revenue growth (CAGR)
-4.90%
3-year earnings per share growth (CAGR)
-40.82%
What the Analysts think about PBYI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Puma Biotechnology stock.
PBYI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
PBYI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
PBYI News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Puma Biotechnology stock?
Puma Biotechnology (PBYI) has a market cap of $137M as of October 26, 2024.
What is the P/E ratio for Puma Biotechnology stock?
The price to earnings (P/E) ratio for Puma Biotechnology (PBYI) stock is 15.38 as of October 26, 2024.
Does Puma Biotechnology stock pay dividends?
No, Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders as of October 26, 2024.
When is the next Puma Biotechnology dividend payment date?
Puma Biotechnology (PBYI) stock does not pay dividends to its shareholders.
What is the beta indicator for Puma Biotechnology?
Puma Biotechnology (PBYI) has a beta rating of 1.07. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.